Aileron Therapeutics Garners $12,000,000 Series D Financing
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=22a75b16-902c-49d4-8401-dc995286b9cf&Preview=1
Date 1/14/2013
Company Name Aileron Therapeutics
Mailing Address 281 Albany St. Cambridge, MA 02139
Company Description Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeutics
for the treatment of cancer and other diseases. Aileron’s technology is the first and
only process that allows peptides to penetrate cells in a sequence-independent manner. Aileron is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by small molecule or biological drugs.
Proceeds Purposes Proceeds from this tranche will be directed to the clinical development of ALRN-5281 in patients with orphan endocrine disorders early this year. Initiation of the ALRN-5281 clinical trial will mark the first-ever Stapled Peptide human clinical trial.